Data missing for daytime symptoms on 1 subject, nocturnal symptoms in 2 subjects, SABA use in 15 subjects, functional status on 12 subjects.†Only 2 subjects used omalizumab: 1 in Group 2 and 1 in Grou
aDuring follow-up, three patients made a plan for pregnancy, and all of them were in the SRVPA group.bRR = Relative risk.cDefined as the patient discontinuing SRVPA or topiramate treatment on his or h
BackgroundPersons with lymphatic filariasis (LF) are often co-infected with soil-transmitted helminths. A single co-administered dose of ivermectin/diethylcarbamazine/albendazole (IDA) is recommended
PDF of Supplementary Material #1) Supplementary Figure: Flow Chart Documentation of Reasoning for Patient Exclusion #2) Supplementary Table: Comparison of HS-Related Medications Before and After GLP-1